Malignant Pleural Mesothelioma Market Drug Class (Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine and Combination, Vinorelbine and Combination and Other Combination), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26
- Published Date: March 2020
- Report ID: BWC19437
- Available Format: PDF
- Page: 180
Report Overview
Global Malignant Pleural Mesothelioma Market Forecast and Trends
The global Malignant Pleural Mesothelioma market has reached USD Billion in 2019 and estimated to reach USD Billion in 2026 and anticipated to grow by CAGR of 7.6% during the forecast period 2020-2026. The global market for malignant pleural mesothelioma will likely incur a favorable boost from increased healthcare spending seen in multiple parts of the world, coupled with the availability of better treatment prognosis for malignant pleural mesothelioma. Overall, the global malignant mesothelioma market is also seeing increased adoption of combination therapies. In the treatment of malignant pleural mesothelioma, many companies promote the increasing use of chemotherapy and immune-oncology procedures.
Global Malignant Pleural Mesothelioma Market: Overview
Malignant pleural mesothelioma is a rare and aggressive cancer that develops around the lungs in a thin layer of tissue called pleura. The microscopic inhalation of asbestos fibers causes malignant pleural mesothelioma. Once the person is inhaling asbestos particles, the human body fails to remove asbestos needle-like fibers from the lungs. The incidence of malignant pleural mesothelioma in Europe is around 20 per million inhabitants, according to the NIH, and it is increasing globally. This will then require the need to develop innovative treatments for malignant pleural mesothelioma, which will drive market growth. Malignant pleural mesothelioma signs include dyspnea, recurrent dry or raspy cough, chest pain, difficulty swallowing, also known as dysphagia, and also known as hemoptysis, coughing up the blood. Since the mid 20th century, the occurrence of Malignant pleural mesothelioma has increased. The appearance of malignant pleural mesothelioma within and between nations is markedly variable.
Growth Drivers
Rising exposure to asbestos (industrial pollutant)
People exposed to asbestos are at a higher risk of developing malignant pleural mesothelioma. Within contaminated areas, the chance of malignant pleural mesothelioma is increased by 2 to 10 fold as compared with non-polluted areas. Besides, people exposed to a high dose of radiation, zeolites (minerals chemically associated with asbestos), and suffering from simian virus 40 are at risk of developing malignant pleural mesothelioma and indirectly contribute to the global market for malignant pleural mesothelioma with the significant growth rate.
Increasing expenditure on R&D coupled with increasing pipeline molecule
The therapeutic pipeline is expected to see significant growth in the forthcoming years on the market for malignant pleural mesothelioma due to higher incidence rates, increased air pollution, increased geriatric population, and increased healthcare expenditure. In addition, the advancement of innovative therapy and the launch of advanced treatment options are likely to provide the malignant pleural mesothelioma market with lucrative growth opportunities over the 2020-2026 forecast period.
Restraint
Delay in Diagnosis
The key factor expected to hamper the growth of the global market for malignant pleural mesothelioma is a long latent period between onset and symptom, lack of effective treatment, and low surveillance rates over the 202-2026 forecast period.
Global Malignant Pleural Mesothelioma Market: Drug Class
Based on drug class, the global malignant pleural mesothelioma market segmented into Premetrexed and Combination, Cisplatin and Combination, Carboplatin and Combination, Gemcitabine, and Combination, Vinorelbine and Combination and Other Combination. Among the group is considered a combination of pemetrexed and cisplatin as the normal first-line treatment of malignant pleural mesothelioma. It is the most effective treatment for Chemotherapy. In a recent study to test cisplatin and pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial (MAPS), the addition of bevacizumab showed significantly improved survival rates for patients with minimal side effects of malignant pleural mesothelioma.
Global Malignant Pleural Mesothelioma Market: Distribution Channel
Based on Distribution Channel, the market is diversified as hospital pharmacies, retail pharmacies, and oncology centers. Amidst the category oncology centers expected to cater global malignant pleural mesothelioma market with a high growth rate. Followed by oncology centers, hospital pharmacies, and retail pharmacies anticipated to witness significant growth rate during the forecast period of 2020-2026.
Global Malignant Pleural Mesothelioma Market: Regional Insights
Global Malignant Pleural Mesothelioma market segmented into five regions, including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading the market for malignant pleural mesothelioma, followed by Europe due to higher incidence and prevalence rates, an increase in the geriatric population, and increased demand advance therapy. The Asia Pacific is an emerging market for malignant pleural mesothelioma due to the development of healthcare infrastructure, patient awareness, and increased government spending in the healthcare sector. Low recognition of patients, lack of proper care, and high therapy costs are factors that narrow the Middle East & Africa market for malignant pleural mesotheliomas.
Malignant Pleural Mesothelioma: Competitive Landscape
Malignant Pleural Mesothelioma market is fragmented owing to the presence of number of large-sized companies that hold the majority share of AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp and Other Prominent Players.
The objective of the Study:
To analyze and forecast the global market size of the Malignant Pleural Mesothelioma.
Analyzing careful market segmentation and estimating value-based market size through region-based segmentation.
The global Malignant Pleural Mesothelioma is divided into five regions: North America, Europe, Asia-Pacific, Middle East & Africa, Latin America.
To outline, categorize, and forecast the global AI in the agricultural market based on drug class, route of administration, and distribution channel with the region.
To examine competitive developments in the global Malignant Pleural Mesothelioma market, such as technological advancement, services, and regulatory framework.
To emphasize the impact study of market dynamics variables such as users, constraints, opportunities, and challenges.
Profiling key players strategically and analyzing their market shares comprehensively, together with detailing the competitive environment for market leaders.
Scope of the Report:
|
Attribute |
Details |
|
Years Considered |
Historical data – 2016-2019 |
|
Base Year – 2019 |
|
|
Forecast – 2020 – 2026 |
|
|
Facts Covered |
Revenue in USD Million/Billion |
|
Market Coverage |
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia |
|
Product/Service Segmentation |
By Drug Class, Route of Administration, and Distribution Channel |
|
Key Players |
AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan NV, Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Other Prominent Players. |
By Drug Class
· Pemetrexed and Combination
· Cisplatin and Combination
· Carboplatin and Combination
· Gemcitabine and Combination
· Vinorelbine and Combination
· Other Combination
By Route of Administration
· Oral
· Parenteral
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Oncology Centers
By Region:
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East & Africa
Business Questions Answer by the Report
How will the market drivers, restraints, and opportunities affect the market dynamics?
What will be the market size in terms of value and volume and market statistics with a detailed classification?
Which segment dominates the market or region, and one will be the fastest-growing, and why?
A comprehensive survey of the competitive landscape and the market participant players
Analysis of strategy adopted by the key player and their impact on other players.
Customization Scope for the Client
Client satisfaction is our first and last priority, and that’s why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:
Additional Company Information
With five additional company detail analysis
Additional country analysis
Detailed segment analysis
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Market Size Estimation
2.6. Assumption for The Study
2.7. Market Breakdown & Data Triangulation
3. Executive Summary
4. Global Malignant Pleural Mesothelioma Insights
4.1. DROC Analysis
4.1.1. Growth Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Regulatory Framework
4.4. Company Market Share Analysis, 2019
4.5. Porter’s Five forces analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. Global Malignant Pleural Mesothelioma Market Overview
5.1. Market Size & Forecast by Value, 2016-2026
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast 2016-2026
5.2.1. By Route of Administration
5.2.1.1. Oral
5.2.1.2. Parenteral
5.2.2. By Drug Class
5.2.2.1. Pemetrexed and Combination
5.2.2.2. Cisplatin and Combination
5.2.2.3. Carboplatin and Combination
5.2.2.4. Gemcitabine and Combination
5.2.2.5. Vinorelbine and Combination
5.2.2.6. Other Combination
5.2.3. By Distribution Channel
5.2.3.1. Hospital Pharmacies
5.2.3.2. Retail Pharmacies
5.2.3.3. Oncology Centers
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia Pacific
5.2.4.4. Latin America
5.2.4.5. Middle East & Africa
6. North America Malignant Pleural Mesothelioma Market
6.1. Market Size & Forecast by Value, 2016-2026
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast 2016-2026
6.2.1. By Route of Administration
6.2.2. By Drug Class
6.2.3. By Distribution Channel
6.2.4. By Country
6.2.4.1. U.S
6.2.4.2. Canada
7. Europe Malignant Pleural Mesothelioma Market
7.1. Market Size & Forecast by Value, 2016-2026
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast 2016-2026
7.2.1. By Route of Administration
7.2.2. By Drug Class
7.2.3. By Distribution Channel
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. U.K
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Spain
7.2.4.6. Rest of Europe
8. Asia Pacific Malignant Pleural Mesothelioma Market
8.1. Market Size & Forecast by Value, 2016-2026
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast 2016-2026
8.2.1. By Route of Administration
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia Pacific
9. Latin America Malignant Pleural Mesothelioma Market
9.1. Market Size & Forecast by Value, 2016-2026
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast 2016-2026
9.2.1. By Route of Administration
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Mexico
9.2.4.3. Argentina
9.2.4.4. Rest of Latin America
10. Middle East & Africa Malignant Pleural Mesothelioma Market
10.1. Market Size & Forecast by Value, 2016-2026
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast 2016-2026
10.2.1. By Route of Administration
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of Middle East & Africa
11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
11.1. AstraZeneca Plc.
11.2. Bristol-Myers Squibb Company
11.3. F. Hoffmann-La Roche Ltd.
11.4. Merck & Co., Inc.
11.5. Novartis AG
11.6. Pfizer Inc.
11.7. Sanofi
11.8. Eli Lilly and Company
11.9. Teva Pharmaceuticals
11.10. Boehringer Ingelheim GmbH
11.11. Mylan NV.
11.12. Fresenius Kabi AG
11.13. Sun Pharmaceuticals Industries Ltd
11.14. Corden Pharma International GmbH
11.15. Concordia International Corp
11.16. Other Prominent Players
List of Figures:
Fig: Global Malignant Pleural Mesothelioma Segmentation
Fig: Company Market Share Analysis, 2019
Fig: Global Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Global Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: Global Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Global Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Global Malignant Pleural Mesothelioma Market Share, By Region, By Value, 2016-2026
Fig: North America Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: North America Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: North America Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: North America Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: North America Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: North America Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Europe Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Europe Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Europe Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: Europe Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Europe Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
Fig: Middle-East & Africa Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026
Fig: Middle-East & Africa Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026
Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026
Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026
Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026
Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026
List of Tables:
Table: Global Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: Global Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Global Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Global Malignant Pleural Mesothelioma Market Size, By Region, By Value, 2016-2026
Table: North America Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: North America Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: North America Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: North America Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Europe Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: Europe Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Europe Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Europe Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Latin America Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: Latin America Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Latin America Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Latin America Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026
Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026
Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026
Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026
Table: AstraZeneca Plc. Financial Analysis
Table: Bristol-Myers Squibb Company Financial Analysis
Table: F. Hoffmann-La Roche Ltd. Financial Analysis
Table: Merck & Co., Inc. Financial Analysis
Table: Novartis AG Financial Analysis
Table: Pfizer Inc. Financial Analysis
Table: Sanofi Financial Analysis
Table: Eli Lilly and Company Financial Analysis
Table: Teva Pharmaceuticals Financial Analysis
Table: Boehringer Ingelheim GmbH Financial Analysis
Table: Mylan NV. Financial Analysis
*Financial Information of non-listed companies will be provided as per the availability
**The segmentation and the companies are subjected to modification based on the in-depth secondary for the final deliverable.
Market Segmentation
By Drug Class
· Pemetrexed and Combination
· Cisplatin and Combination
· Carboplatin and Combination
· Gemcitabine and Combination
· Vinorelbine and Combination
· Other Combination
By Route of Administration
· Oral
· Parenteral
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Oncology Centers
By Region:
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East & Africa
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.